LILRB2

LILRB2 Molekülinformation

Englischer Name	Leukocyte immunoglobulin-like receptor subfamily B member 2	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	11	Target-Alias	Leukocyte immunoglobulin-like receptor 2，CD85 antigen-like family member D，Immunoglobulin-like transcript 4，ILT-4，Monocyte/macrophage immunoglobulin-like receptor 10，MIR-10，CD_antigen: CD85d，LILRB2，Leukocyte Immunoglobulin Like Receptor B2，Leucocyte Ig-Like Receptor B2，MIR10，Leukocyte Immunoglobulin-Like Receptor， Subfamily B (With TM And ITIM Domains)， Member 2，Ig-Like Transcript 4，Myeloid Inhibitory Receptor 10，CD85d Antigen，ILT4，LIR2，CD85d，LIR-2，LIRB2
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Leukocyte immunoglobulin-like receptor subfamily B member 2
Target-Alias	Leukocyte immunoglobulin-like receptor 2，CD85 antigen-like family member D，Immunoglobulin-like transcript 4，ILT-4，Monocyte/macrophage immunoglobulin-like receptor 10，MIR-10，CD_antigen: CD85d，LILRB2，Leukocyte Immunoglobulin Like Receptor B2，Leucocyte Ig-Like Receptor B2，MIR10，Leukocyte Immunoglobulin-Like Receptor， Subfamily B (With TM And ITIM Domains)， Member 2，Ig-Like Transcript 4，Myeloid Inhibitory Receptor 10，CD85d Antigen，ILT4，LIR2，CD85d，LIR-2，LIRB2
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	11
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

LILRB2 Produktliste

Attribut
Protein (6)
Produktbibliothek
Online (6)
Spezies
Human (4)Cynomolgus (2)
Etikett
His Tag (2)Fc Tag & Avi Tag (1)His Tag & Avi Tag (2)Fc Tag (1)
Marker
Unconjugated (3)Biotin-labeled (3)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT LI2-H5220	Human	HEK293	Human LILRB2 / CD85d / ILT4 Protein, His Tag, low endotoxin (MALS verified)	In den Warenkorb legen
HOT LI2-H5253	Human	HEK293	Human LILRB2 / CD85d / ILT4 Protein, Fc Tag (MALS verified)	In den Warenkorb legen
HOT LI2-H82E7	Human	HEK293	Biotinylated Human LILRB2 / CD85d / ILT4 Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
HOT LI2-H82F5	Human	HEK293	Biotinylated Human LILRB2 / CD85d / ILT4 Protein, Fc,Avitag™ (MALS verified)	In den Warenkorb legen
LI2-C52H3	Cynomolgus	HEK293	Cynomolgus LILRB2 / CD85d / ILT4 Protein, His Tag	In den Warenkorb legen
LI2-C82E3	Cynomolgus	HEK293	Biotinylated Cynomolgus LILRB2 / CD85d / ILT4 Protein, His,Avitag™	In den Warenkorb legen

Gesamtmenge6

LILRB2 Molekülhintergrund

Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB2 Molekülalias

LILRB2,ILT4,LIR2,MIR10,CD85d

Antikörperprojekt-Handelsplattform

Projektname	Projektphase	Molekültyp	Molekülquelle	Krankheitsgebiet	Indikationen
LILRB2 mAb - 01	PCC	Monoclonal	Humanized Mouse	Solid Tumor	Solid tumor

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Polzastobart	JTX-8064	Phase 2 Clinical	Jounce Therapeutics Inc	Neoplasms	Details
IO-108	IO-108	Phase 2 Clinical	Yiming Biomedical Technology (Hangzhou) Co Ltd	Liver Neoplasms; Solid tumours	Details
MK-4830	MK-4830	Phase 2 Clinical	Agenus Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Ovarian Neoplasms; Solid tumours	Details
SPX-303	SPX-303	Phase 2 Clinical	SparX Biopharmaceutical Corp	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms	Details
OR-502	OR502; OR-502	Phase 2 Clinical	OncoResponse Inc	Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Skin Melanoma; Solid tumours	Details
NGM-707	NGM-707	Phase 2 Clinical	Merck & Co, NGM Biopharmaceuticals Inc	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Glioblastoma; Melanoma; Mesothelioma; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms	Details
AK-150 (Akeso)	AK150; AK-150	Phase 1 Clinical		Solid tumours	Details
CHS-1000	CHS-1000	Phase 1 Clinical	Coherus Biosciences Inc	Solid tumours	Details
BMS-986406	BMS-986406; ONO-7226	Phase 1 Clinical	Bristol-Myers Squibb Company	Neoplasms	Details
CDX-585	CDX-585; BSI-585	Phase 1 Clinical	Biosion Inc, Celldex Therapeutics	Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms	Details
ES-009	ES-009	Phase 1 Clinical	Elpiscience (Shanghai) Biopharma Ltd	Neoplasms; Solid tumours	Details